ClinConnect ClinConnect Logo
Search / Trial NCT04278261

Comparison H-FIRE and Laparoscopic RP in Treating Men With Localized Prostate Cancer

Launched by SHANGHAI EAST HOSPITAL · Feb 19, 2020

Trial Information

Current as of August 19, 2025

Not yet recruiting

Keywords

Focal Therapy Radical Prostatectomy High Frequency Irreversible Electroporation Prostate Cancer

ClinConnect Summary

This clinical trial is looking at two different ways to treat men with localized prostate cancer: high-frequency irreversible electroporation (H-FIRE) and laparoscopic radical prostatectomy (Laparoscopic RP). The goal is to see which method works better in terms of patient health and cancer control. H-FIRE is a newer technique that uses electrical pulses to destroy cancer cells, while laparoscopic RP involves surgically removing the prostate using smaller incisions.

To participate, men must be under 80 years old, have a specific level of prostate-specific antigen (PSA) in their blood, and have a certain stage of cancer that hasn't spread. They should also understand the study and agree to take part by signing a consent form. Participants will not be eligible if they have had previous cancer treatments, certain recent surgeries, or other conditions that would make it unsafe for them to join. This trial is not yet recruiting participants, but it aims to provide valuable information on the best treatment options for prostate cancer in the future.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age less than 80 years old.
  • 2. PSA\<20ng/ml.
  • 3. Clinical stage ≤T2c.
  • 4. Biopsy Gleason score ≤4+4.
  • 5. No evidence of metastasis.
  • 6. Fully understand the clinical trial protocol and sign the informed consent
  • Exclusion Criteria:
  • 1. Any previous treatment to PCa.
  • 2. Any previous surgery within 3 months.
  • 3. Contraindications to MRI, bone scan, or PSMA-PET (eg, metal implant, contrast agent allergy).
  • 4. History of any other malignant tumour.
  • 5. Any other conditions that make the investigator judge that participants are not suitable for this trial.

About Shanghai East Hospital

Shanghai East Hospital, affiliated with Tongji University, is a leading healthcare institution in China dedicated to providing high-quality medical services, education, and research. Renowned for its advanced clinical practices and cutting-edge technologies, the hospital plays a pivotal role in the advancement of medical science through innovative research and clinical trials. Committed to improving patient outcomes, Shanghai East Hospital collaborates with various stakeholders to explore new therapies and treatment modalities, enhancing the collective understanding of health and disease. Their clinical trial initiatives focus on addressing pressing medical needs while ensuring the highest ethical standards and patient safety.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Haifeng Wang, MD

Principal Investigator

Shanghai East Hospital,Tongji University School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials